[Isoniazid-induced hepatic failure. Report of a case].
Isoniazid and pyrazinamide are both well-known hepatotoxic drugs. When isoniazid is used, the hepatic lesion appears before than when pyrazinamide is used. This paper intends to relate a case of a 5-month-old patient who had lungs' and meningeal tuberculosis and who developed toxic hepatitis accomplished by hepatic failure while he was being treated with isoniazid, pyrazinamide and rifampicin. The clinic manifestations and the laboratory alterations were detected in the fifth day of treatment and the recovery was fast; and almost complete by the end of the first week, in which the use of isoniazid had been suspended. Although it was necessary to take the patient to the intensive care unit, he had a good recovery, without sequels.
Pereira
R M
RM
Departamento de Pediatria da Faculdade de Ciências Médicas, Universidade Estadual de Campinas. rmpereira@uol.com.br
Tresoldi
A T
AT
Hessel
G
G
D000995:Antitubercular Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D004359:Drug Therapy, Combination; D006801:Humans; D007223:Infant; D007538:Isoniazid / Q000009:adverse effects*; D017114:Liver Failure, Acute / Q000139:chemically induced*; D008297:Male; D011718:Pyrazinamide / Q000009:adverse effects; D012293:Rifampin / Q000009:adverse effects; D014390:Tuberculosis, Meningeal / Q000097:blood / Q000188:drug therapy*; D014397:Tuberculosis, Pulmonary / Q000097:blood / Q000188:drug therapy*
D000995:Antitubercular Agents; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin